Empagliflozin in the treatment of heart failure
Authors:
- 25 April 2024
- journal article
- review article
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (5-6) , 251-261
Abstract
Heart failure (HF) affects more than 60 million individuals globally. Empagliflozin is currently approved for type 2 diabetes and chronic HF. Clinical trials have demonstrated that empagliflozin reduces the composite end point of hospitalizations for HF and mortality and improves the quality of life irrespective of left ventricular ejection fraction. Empagliflozin is a once-daily medication with minimal drug-drug interactions and does not require titration. Empagliflozin causes mild weight loss and does not significantly reduce blood pressure. Empagliflozin acts as an enabler for other HF drugs by reducing the risk of hyperkalemia. Empagliflozin is also beneficial for chronic kidney disease which exists commonly with HF. This review outlines the pharmacokinetics, pharmacodynamics, safety, and efficacy of empagliflozin in HF across various sub-groups and settings.Keywords
This publication has 72 references indexed in Scilit:
- Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection FractionJAMA Cardiology, 2023
- Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF TrialEuropean Journal of Heart Failure, 2022
- Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trialEuropean Journal of Heart Failure, 2022
- Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐ReducedEuropean Journal of Heart Failure, 2022
- Effects of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function in Patients with Chronic Heart FailureESC Heart Failure, 2021
- Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection FractionJAMA Cardiology, 2021
- Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trialEuropean Journal of Heart Failure, 2021
- Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failureEuropean Journal of Heart Failure, 2020
- Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)European Journal of Heart Failure, 2020
- Clinical Practice Update on Heart Failure 2019: Pharmacotherapy, Procedures, Devices and Patient Management. An Expert Consensus Meeting Report of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2019